Paloxi 0.5 Tablet
by Beacon Pharmaceuticals Limited
৳20.06
Square Pharmaceuticals Limited
Palonosetron is used to treat nausea and vomiting, both acute and delayed.
Nausea and vomiting that are out of control
Chemotherapy-induced nausea and vomiting (CINV): Acute CINV caused by certain types of chemotherapy on the day of treatment.
With certain types of chemotherapy, delayed CINV can result in symptoms a few days later.
Nausea and vomiting caused by radiotherapy (RINV)
Palonosetron is a 5-HT3 antagonist with a high affinity for this receptor and little or no affinity for other receptors. Chemotherapeutic agents are thought to cause nausea and vomiting by releasing serotonin from enterochromaffin cells in the small intestine, which then activates 5-HT3 receptors on nerve terminals.
Typical dosage: Adults should take 0.5 mg of the tablet once a day. Adult IV dosage: A single 0.075 mg IV dose should be given over 10 seconds.
Nausea and vomiting caused by chemotherapy: Adult tablet dosage: 0.5 mg, given 1 hour before the start of chemotherapy. Adult IV dosage: 30 minutes before, a single 0.25 mg IV dose should be administered over 30 seconds.
Palonosetron injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents in controlled clinical trials. In murine tumor models, palonosetron had no effect on the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin, or mitomycin C.
Palonosetron is not recommended for patients who have a history of hypersensitivity to the drug or any of its ingredients.
Headaches and constipation are the most common side effects.
'B' pregnancy category. Palonosetron is not known to be excreted in breast milk.
In elderly patients over the age of 65, no dosage adjustments are recommended.
Anti-emetic medications
Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.